Labcorp

LH

Capitalización de mercado USD 25.8 mil M

OPK's $722M BioReference asset sale to Labcorp, with a potential $150M earnout, aims to sharpen its biopharma focus and expand access to the 4Kscore Test.

Labcorp Holdings Inc. (NYSE:LH) stock traded higher Thursday after the company agreed to acquire select assets of BioReference Health from OPKO Health Inc. (NASDAQ:OPK) in a deal worth up to $872 million.

Third-quarter earnings season has opened unevenly. JPMorgan, Wells Fargo and Citigroup posted missed results this week, while UnitedHealth topped forecasts for both revenue and profit.

Acquisition will expand access to clinical laboratory services, including a broad specialty testing menu for patients and providers nationwide BURLINGTON, N.C. and MIAMI, Fla.

First lab test offered in collaboration with Thrive Global Combines Labcorp's scientific expertise with Thrive Global's behavior change approach to help consumers turn health insights into healthier daily habits Delivers insights from five key cardiometabolic health indicators paired with educational content and recommended Thrive Microsteps® BURLINGTON, N.C., Oct. 13, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of the Thrive 5 Health Test, the first lab test offered in collaboration with Arianna Huffington's behavior change technology company, Thrive Global.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

BURLINGTON, N.C., Sept. 30, 2026 /PRNewswire/ -- Labcorp Holdings Inc.

LH expands specialty testing and consumer services through acquisitions, partnerships and AI, while reimbursement and cost risks remain.

Labcorp shares dropped sharply after CMS released preliminary 2027 lab-payment rates, aligning Medicare rates closer to private insurers and targeting $1B annual savings. I see the selloff as overdone, with market fears exaggerated by a misunderstanding of the CMS report's impact on LH's bottom line. The proposed cuts only affect Medicare's Clinical Laboratory Fee Schedule, with annual reimbursement reductions capped at 15% and final rates pending.

Labcorp Holdings Inc. is upgraded to Buy, supported by resilient demand for diagnostics and robust Q2 results, despite upcoming Medicare rate cuts. LH outperformed both the S&P 500 and healthcare peers YTD, with strong technical support and positive operating margins. Revenue durability, new test launches, and a diversified biopharma segment bolster LH's growth and risk profile amid regulatory headwinds.